Company: PTPI
Filing Date: 2025-03-07
Form Type: PRE 14A
Source: 0001104659-25-021794
Chunk: 70

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-07
Form: PRE 14A
Chunk 70
---
 of Common Stock issuable upon exercise of the Warrants (“Warrant Shares”). If we are prevented from
issuing the applicable Conversion Shares upon conversion of the Series A Preferred Stock by the holder thereof, in lieu of delivering
such applicable Conversion Shares to such holder, we would be required to redeem such shares of Series A Preferred Stock at a price
equal to the sum of (i) the product of (x) such number of applicable Conversion Shares as are unavailable for issue and (y) the
greatest closing sale price of the Common Stock on any trading day during the period commencing on the date such holder delivers the applicable
conversion notice to the Company and ending on the date of our issuance and payment to such holder and (ii) certain fees. If we do
not have sufficient cash resources to make these payments, we may need to delay, reduce or eliminate certain research and development
programs or other operations, sell some or all of our assets or merge with another entity.

Additionally, if this proposal
is not approved by our stockholders, our financing alternatives will be limited by the lack of any available unissued and unreserved
authorized shares of Common Stock, and stockholder value may be harmed by this limitation. In addition, our future success depends upon
our ability to attract, retain and motivate highly-skilled employees, and if this proposal is not approved by our stockholders, the lack
of any available unissued and unreserved authorized shares of Common Stock to provide future equity incentive opportunities could adversely
impact our ability to achieve these goals. In short, if our stockholders do not approve this proposal, we may not be able to access the
capital markets, complete corporate collaborations, partnerships or other strategic transactions, attract, retain and motivate employees,
and pursue other business opportunities integral to our growth and success.

Further, unless we obtain Share Increase Stockholder Approval for this
proposal, we will be required to incur additional costs in order to hold additional stockholder meetings to seek such approval.

Rights of Additional Authorized Shares

If and when issued, the additional Common Stock
to be authorized by adoption of the Share Increase Amendment would have rights and privileges identical to our currently outstanding
Common Stock. Those rights do not include preemptive rights with respect to the future issuance of any additional shares of Common Stock.

Potential Adverse Effects of Increase in Authorized Common Stock

The authorization of additional
shares of Common Stock sought by this proposal would not have any immediate dilutive effect upon the proportionate voting power or rights
of our existing